Early Type 1 diabetes experience created durable empathy for loss of control, anticipatory anxiety and treatment fatigue, ...

Approval covers all current IV isatuximab indications and introduces the first oncology product labeled for both OBI and manual SC administration. IRAKLIA (NCT05405166) established noninferiority of ...

FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration. The US Food and Drug Administration (FDA) has ...

Subcutaneous isatuximab is now approved with pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/lenalidomide/dexamethasone, aligning SC ...

Dear Dr. Roach: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn't successful. I was told that surgery after ...

DEAR DR. ROACH: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn’t successful. I was told that surgery after ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater ...